title: Deferasirox: appraisal of safety and efficacy in long-term therapy.
abstract: Deferasirox is a once-daily, oral iron chelator that is widely used in the management of patients with transfusional hemosiderosis. Several Phase II trials along with their respective extension studies as well as a Phase III trial have established the efficacy and safety of this novel agent in transfusion-dependent patients with β-thalassemia, sickle-cell disease and bone marrow-failure syndromes, including myelodysplastic syndrome and aplastic anemia. Data from various clinical trials show that a deferasirox dose of 20 mg/kg/day stabilizes serum ferritin levels and liver iron concentration, while a dose of 30-40 mg/kg/day reduces these parameters and achieves negative iron balance in red cell transfusion-dependent patients with iron overload. Across various pivotal clinical trials, deferasirox was well tolerated, with the most common adverse events being gastrointestinal disturbances, skin rash, nonprogressive increases in serum creatinine, and elevations in liver enzyme levels. Longer-term extension studies have also confirmed the efficacy and safety of deferasirox. However, it is essential that patients on deferasirox therapy are monitored regularly to ensure timely management for any adverse events that may occur with long-term therapy.
authors: Jane Ann Nohl Division of Hematology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
authors: Preeti
authors: P
authors: Chaudhary
authors: Vinod
authors: V
authors: Pullarkat
keywords: deferasirox; iron overload; myelodysplastic syndrome; sickle-cell disease; thalassemia
references: Lancet. 1989 Jul 1;2(8653):27-30
references: 2567801
references: Eur J Clin Invest. 2009 May;39(5):406-11
references: 19320908
references: Gastroenterology. 2011 Oct;141(4):1202-11, 1211.e1-3
references: 21741344
references: Br J Haematol. 2011 Aug;154(3):387-97
references: 21592110
references: Haematologica. 2010 Apr;95(4):557-66
references: 19951979
references: Eur J Haematol. 2012 Mar;88(3):260-8
references: 22023452
references: J Natl Compr Canc Netw. 2011 Jan;9(1):30-56
references: 21233243
references: Int J Hematol. 1991 Oct;54(5):371-5
references: 1756248
references: Am J Pediatr Hematol Oncol. 1992 Spring;14(1):48-56
references: 1550263
references: Hematol Oncol Clin North Am. 2004 Dec;18(6):1355-77, ix
references: 15511620
references: Acta Haematol. 2012;128(2):113-8
references: 22760067
references: Transfusion. 2007 Oct;47(10):1919-29
references: 17880620
references: Haematologica. 2002 Dec;87(12):1286-306
references: 12495903
references: J Clin Pharmacol. 2003 Jun;43(6):565-72
references: 12817519
references: Ann Hematol. 2011 Jan;90(1):1-10
references: 20938663
references: Br J Haematol. 2007 Feb;136(3):501-8
references: 17233848
references: Haematologica. 2004 Oct;89(10):1187-93
references: 15477202
references: Blood. 2006 May 1;107(9):3455-62
references: 16352812
references: Blood Rev. 2012 Apr;26 Suppl 1:S16-9
references: 22631036
references: Eur J Haematol. 2008 Feb;80(2):168-76
references: 18028431
references: Eur J Haematol. 2012 May;88(5):431-8
references: 22335829
references: Blood. 2003 Sep 1;102(5):1583-7
references: 12763939
references: Hematol J. 2000;1(3):153-8
references: 11920184
references: Blood. 2010 Mar 25;115(12):2364-71
references: 19996412
references: Haematologica. 2013 Jul;98(7):1045-8
references: 23585526
references: Am J Dis Child. 1990 May;144(5):565-9
references: 2330923
references: Leuk Res. 2010 Sep;34(9):1143-50
references: 20451251
references: Br J Haematol. 2001 Nov;115(2):239-52
references: 11703317
references: Haematologica. 2012 Jun;97(6):842-8
references: 22271905
references: Nat Rev Neurosci. 2013 Aug;14(8):551-64
references: 23820773
references: Haematologica. 2012 Sep;97(9):1364-71
references: 22419577
references: Acta Haematol. 1996;95(1):26-36
references: 8604584
references: Br J Haematol. 2002 Jul;118(1):330-6
references: 12100170
references: Eur J Haematol. 2009 Jun;82(6):458-65
references: 19187278
references: Expert Opin Drug Saf. 2007 May;6(3):235-9
references: 17480173
references: Semin Hematol. 2005 Apr;42(2 Suppl 1):S19-21
references: 15846581
references: Blood Cells Mol Dis. 2006 Jul-Aug;37(1):12-20
references: 16737833
references: Blood. 2011 Jul 28;118(4):884-93
references: 21628399
references: Ann Hematol. 2013 Jan;92(2):191-8
references: 23073603
references: J Pediatr. 2001 Dec;139(6):785-9
references: 11743502
references: Blood. 2009 Dec 17;114(26):5251-5
references: 19710499
references: Ann Hematol. 2009 Apr;88(4):301-10
references: 18758781
references: Lancet. 2003 May 10;361(9369):1597-602
references: 12747879
references: Hematology Am Soc Hematol Educ Program. 2001;:47-61
references: 11722978
references: J Pediatr. 2005 Aug;147(2):244-7
references: 16126058
references: Hematology Am Soc Hematol Educ Program. 2002;:136-61
references: 12446422
references: Adv Exp Med Biol. 2002;509:185-203
references: 12572995
references: Br J Haematol. 2003 Jan;120(2):187-200
references: 12542475
references: J Pediatr Hematol Oncol. 2012 May;34(4):247-51
references: 22510772
references: Hepatology. 2010 Nov;52(5):1671-779
references: 20814896
references: Curr Med Chem. 2003 Jun;10(12):1065-76
references: 12678677
references: J Clin Oncol. 2005 Oct 20;23(30):7594-603
references: 16186598
references: J Clin Oncol. 2012 Jun 10;30(17):2134-9
references: 22547607
references: Blood. 2007 May 15;109(10):4586-8
references: 17234738
references: N Engl J Med. 1998 Jul 2;339(1):5-11
references: 9647873